When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis
Authors:
- 25 March 2015
- journal article
- review article
- Published by Springer Nature in Head and Neck Pathology
- Vol. 9 (1) , 16-23
Abstract
Thyroid carcinomas of follicular epithelial derivation are common and generally well-behaved malignancies with excellent cure and survival rates. However, a subset of these carcinomas, whether well-differentiated, poorly differentiated, or anaplastic, is highly aggressive, manifesting with local invasion, recurrence, and distant metastasis. The recognition of dedifferentiation is of paramount importance. In addition, the challenge for Pathologists is to identify the rare aggressive differentiated carcinomas so that treatment may be tailored appropriately. Thus, histological subtyping and documentation of other aggressive features such as widespread invasion and angioinvasion are critical. Mutational analyses in the past decade have delineated the molecular alterations responsible for thyroid carcinogenesis and progression, allowing greater sub-classification and prognostication of thyroid carcinomas. This review article highlights important aggressive morphologic features and molecular mutations associated with thyroid carcinoma.Keywords
This publication has 36 references indexed in Scilit:
- Highly prevalent TERT promoter mutations in aggressive thyroid cancersEndocrine-Related Cancer, 2013
- Comprehensive Literature Review: Recent Advances in Diagnosing and Managing Patients with Poorly Differentiated Thyroid CarcinomaInternational Journal of Endocrinology, 2013
- Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expressionLaboratory Investigation, 2010
- Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patternsLaboratory Investigation, 2010
- The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancerMolecular and Cellular Endocrinology, 2010
- Standard and Emerging Therapies for Metastatic Differentiated Thyroid CancerThe Oncologist, 2010
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathwayProceedings of the National Academy of Sciences, 2009
- Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer ProgressionCancer Research, 2007
- Follicular thyroid carcinoma: Histology and prognosisCancer, 2004
- Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma: An Unusually High Prevalence of ras MutationsAmerican Journal of Clinical Pathology, 2003